| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb2612f4846bb8acc5d5f4439caf662e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16122 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-385 |
| filingDate |
2004-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2009-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a09b3844213ec015b4dd938d59d246b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00ee5131726a0ceb56a814f57391de83
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a85231c64fbe9178d44e291fbec0938a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf05650a9b4f4efd957dd0ea1645bebd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85257965b0d8e18dcf3c2365ae961c1f |
| publicationDate |
2009-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7608271-B2 |
| titleOfInvention |
Modified human immunodeficiency virus anti-fusogenic GP41 peptides comprising a maleimide-containing group |
| abstract |
Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8541550-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8507277-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8952133-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8927691-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8470972-B2 |
| priorityDate |
1999-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |